LAM561 BEATS PANCREATIC CANCER project is totally aligned with the impacts expected in the work program as it proposes the development of a new drug (LAM561) for patients living with pancreatic cancer. Pancreatic cancer is the fourth most fatal cancer. Pancreatic cancer is a deathly pathology that in 2020 affected approximately 1.8 in 10,000 people in the European Union (EU) in 2019. This was equivalent to a total of around 93,000 people, and is below the ceiling for orphan designation, which is 5 people in 10,000 (estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein). This represents a population of 518,400,000 (Eurostat 2019). Moreover, LAM561 acts through a novel and unique MoA, activating SGMS, a target never previously described for any other currently marketed anticancer drug. In pancreatic cancer innovative therapeutic approaches are demanded. Moreover, as results of this project are positive, the proposal will contribute to deliver a new non-toxic therapy for this rare disease, having a major impact on life expectancy and quality of life of patients with pancreatic cancer. Laminar Pharmaceuticals, in accordance with the ‘European Charter for Researchers’ confirms that the researcher will secure the benefits of the exploitation of R&D results through legal protection and through appropriate protection of IPR. Following the H2020 ‘Guidelines for your dissemination and exploitation activities’, and in order to ensure effective exploitation and dissemination of the project, WP0 includes the drafting of a realistic and achievable PEDR covering marketing strategy, dissemination and communication. Pivotal aspects such as market access strategy, pricing and reimbursement and a broad international health economics analysis will be developed during the project in order to define a clear policy to exploit the results of the LAM561 BEATS PANCREATIC CANCER project. Estimated number of newly diagnosed pancreatic cancer patients worldwide will reach almost 150.000 cases by 2018 and projected peak sales of LAM561 could exceed 750M€. This proposal will clearly contribute to strengthen the competitiveness and growth of all participant entities, and particularly that of Laminar Pharmaceuticals, who is currently a world leader in the field of lipid-modulation therapeutics and is well positioned to consolidate this innovative technology and develop new game-changing drugs to address urgent medical needs in serious diseases like cancer or Alzheimer's Disease. These treatments could have not only a remarkable economic impact, leading to important saving to the National Public Health Systems, but also an extraordinary social impact for millions of persons suffering from this condition worldwide.
